Business
GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million
PARIS, March 10, 2026--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/5a8defbcdcff89cde8da77b96da0cfa9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cPSZ3EhusCsss2NNhnxH7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5a8defbcdcff89cde8da77b96da0cfa9","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, March 10, 2026--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics ("GenSight" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion a EUR 1,694,715.5256 fundraising subscribed by three of its shareholders: Heights Capital, Invus and UPMC Enterprises (the "Fundraising"). This fundraising follows the EUR 4.5 million private placement completed in July (in two tranches), the EUR 3.7 million fundraising completed in early October, the EUR 2 million fundraising completed in November and the EUR 2.9 million fundraising completed in December and January. The Fundraising uses a similar structure of shares and warrants, including pre-funded warrants, as detailed further below.","length":887,"tagName":"p"},{"type":"text","content":""Today's news marks a significant operational milestone for GenSight Biologics. With individual patient applications recently approved under the French AAC program and treatments scheduled this month, we are entering a period of clinical delivery across multiple geographies — France, Israel, and the United States," said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "These early access attest to our ability to execute. We are confident about our path forward, and last night's fundraising reflects our commitment to extending our cash runway and advancing to the start of th...